233 related articles for article (PubMed ID: 28977547)
1. Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene.
Saiki M; Ohyanagi F; Ariyasu R; Koyama J; Sonoda T; Nishikawa S; Kitazono S; Yanagitani N; Horiike A; Ninomiya H; Ishikawa Y; Nishio M
Jpn J Clin Oncol; 2017 Dec; 47(12):1189-1192. PubMed ID: 28977547
[TBL] [Abstract][Full Text] [Related]
2. A case of inflammatory myofibroblastic tumor harboring EML4-ALK fusion with a brain metastasis responding to alectinib.
Sakoda S; Tanaka K; Koga Y; Mikumo H; Tsuchiya-Kawano Y; Harada E; Tamiya S; Okamoto I
Thorac Cancer; 2024 Feb; 15(5):415-418. PubMed ID: 38213097
[TBL] [Abstract][Full Text] [Related]
3. FN1: a novel fusion partner of ALK in an inflammatory myofibroblastic tumor.
Ouchi K; Miyachi M; Tsuma Y; Tsuchiya K; Iehara T; Konishi E; Yanagisawa A; Hosoi H
Pediatr Blood Cancer; 2015 May; 62(5):909-11. PubMed ID: 25682942
[TBL] [Abstract][Full Text] [Related]
4. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.
Cools J; Wlodarska I; Somers R; Mentens N; Pedeutour F; Maes B; De Wolf-Peeters C; Pauwels P; Hagemeijer A; Marynen P
Genes Chromosomes Cancer; 2002 Aug; 34(4):354-62. PubMed ID: 12112524
[TBL] [Abstract][Full Text] [Related]
6. Fusion of dynactin 1 to anaplastic lymphoma kinase in inflammatory myofibroblastic tumor.
Wang X; Krishnan C; Nguyen EP; Meyer KJ; Oliveira JL; Yang P; Yi ES; Erickson-Johnson MR; Yaszemski MJ; Maran A; Oliveira AM
Hum Pathol; 2012 Nov; 43(11):2047-52. PubMed ID: 22658521
[TBL] [Abstract][Full Text] [Related]
7. Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status.
Tanaka H; Taima K; Morimoto T; Nakamura K; Tanaka Y; Itoga M; Takanashi S; Okumura K
BMC Res Notes; 2016 Mar; 9():173. PubMed ID: 26987388
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory myofibroblastic tumor with predominant anaplastic lymphoma kinase-positive cells lacking a myofibroblastic phenotype.
Hisaoka M; Shimajiri S; Matsuki Y; Meis-Kindblom JM; Kindblom LG; Li XQ; Wang J; Hashimoto H
Pathol Int; 2003 Jun; 53(6):376-81. PubMed ID: 12787312
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification.
Takeuchi K; Soda M; Togashi Y; Sugawara E; Hatano S; Asaka R; Okumura S; Nakagawa K; Mano H; Ishikawa Y
Clin Cancer Res; 2011 May; 17(10):3341-8. PubMed ID: 21430068
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
[TBL] [Abstract][Full Text] [Related]
11. Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis.
Asao T; Fujiwara Y; Itahashi K; Kitahara S; Goto Y; Horinouchi H; Kanda S; Nokihara H; Yamamoto N; Takahashi K; Ohe Y
Clin Lung Cancer; 2017 Jul; 18(4):e251-e258. PubMed ID: 28065466
[TBL] [Abstract][Full Text] [Related]
12. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor.
Bridge JA; Kanamori M; Ma Z; Pickering D; Hill DA; Lydiatt W; Lui MY; Colleoni GW; Antonescu CR; Ladanyi M; Morris SW
Am J Pathol; 2001 Aug; 159(2):411-5. PubMed ID: 11485898
[TBL] [Abstract][Full Text] [Related]
13. Intraosseous inflammatory myofibroblastic tumor of the mandible with a novel ATIC-ALK fusion mutation: a case report.
Tateishi Y; Okudela K; Kawai S; Suzuki T; Umeda S; Matsumura M; Kioi M; Ohashi K
Diagn Pathol; 2016 Nov; 11(1):132. PubMed ID: 27846861
[TBL] [Abstract][Full Text] [Related]
14. EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer.
Hui B; Zhang J; Shi X; Xing F; Shao YW; Wang Y; Zhang X; Wang S
Jpn J Clin Oncol; 2020 Dec; 50(12):1470-1474. PubMed ID: 32845005
[TBL] [Abstract][Full Text] [Related]
15. Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.
Yoshida T; Hida T; Yatabe Y
Anticancer Drugs; 2016 Jul; 27(6):573-5. PubMed ID: 26938871
[TBL] [Abstract][Full Text] [Related]
16. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors.
Lawrence B; Perez-Atayde A; Hibbard MK; Rubin BP; Dal Cin P; Pinkus JL; Pinkus GS; Xiao S; Yi ES; Fletcher CD; Fletcher JA
Am J Pathol; 2000 Aug; 157(2):377-84. PubMed ID: 10934142
[TBL] [Abstract][Full Text] [Related]
17. I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
Ou SH; Greenbowe J; Khan ZU; Azada MC; Ross JS; Stevens PJ; Ali SM; Miller VA; Gitlitz B
Lung Cancer; 2015 May; 88(2):231-4. PubMed ID: 25736571
[TBL] [Abstract][Full Text] [Related]
18. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors.
Tothova Z; Wagner AJ
Curr Opin Oncol; 2012 Jul; 24(4):409-13. PubMed ID: 22664824
[TBL] [Abstract][Full Text] [Related]
20. A novel KIF5B-ALK fusion in a child with an atypical central nervous system inflammatory myofibroblastic tumour.
Maruggi M; Malicki DM; Levy ML; Crawford JR
BMJ Case Rep; 2018 Oct; 2018():. PubMed ID: 30344149
[No Abstract] [Full Text] [Related]
[Next] [New Search]
